ProMIS Neurosciences, Inc. (NASDAQ:PMN) Director Madge K. Shafmaster Acquires 60,000 Shares

ProMIS Neurosciences, Inc. (NASDAQ:PMN) Director Madge K. Shafmaster purchased 60,000 shares of the firm’s stock in a transaction on Friday, September 20th. The shares were purchased at an average price of $1.25 per share, for a total transaction of $75,000.00. Following the completion of the purchase, the director now directly owns 68,333 shares of the company’s stock, valued at $85,416.25. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website.

ProMIS Neurosciences Price Performance

Shares of NASDAQ PMN traded up $0.07 during midday trading on Tuesday, hitting $1.30. The company’s stock had a trading volume of 106,909 shares, compared to its average volume of 70,907. The business’s fifty day simple moving average is $1.41 and its two-hundred day simple moving average is $1.72. The firm has a market capitalization of $24.65 million, a price-to-earnings ratio of -1.76 and a beta of 0.62. ProMIS Neurosciences, Inc. has a 1 year low of $0.95 and a 1 year high of $3.10.

ProMIS Neurosciences (NASDAQ:PMN) last posted its earnings results on Thursday, August 8th. The company reported ($0.13) EPS for the quarter, beating the consensus estimate of ($0.14) by $0.01. Analysts anticipate that ProMIS Neurosciences, Inc. will post -0.24 EPS for the current fiscal year.

ProMIS Neurosciences Company Profile

ProMIS Neurosciences, Inc discovers and develops antibody therapies and therapeutic vaccines neurodegenerative diseases and other misfolded protein diseases in Canada. The company's proprietary discovery platform comprises ProMIS and Collective Coordinates algorithms to predict novel targets known as disease specific epitopes on the molecular surface of misfolded proteins.